Intervention not reported
Duloxetine RCTs: 26 Participants: 7952 · people with chronic pain Interventions: duloxetine (all doses combined), milnacipran (all doses combined), mirtazapine (all doses…
1 finding from 1 review
no estimate extracted
26 participants
Moderate
Intervention not reported
Milnacipran RCTs: 5 Participants: 3109 · people with chronic pain Interventions: duloxetine (all doses combined), milnacipran (all doses combined), mirtazapine (all doses…
1 finding from 1 review
no estimate extracted
5 participants
Moderate
Intervention not reported
Total studies: 93 Total participants: 22,558 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
The intervention led to lower total studies: 93 Total participants: 22,558; GRADE not reported.
1 finding from 1 review
no estimate extracted
93 participants
GRADE not reported
Intervention not reported
Desvenlafaxine high dose RCTs: 2 Participants: 905 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
1 finding from 1 review
no estimate extracted
2 participants
Very low
Intervention not reported
Mirtazapine standard dose RCTs: 2 Participants: 457 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
1 finding from 1 review
no estimate extracted
2 participants
Very low
Intervention not reported
Duloxetine standard dose RCTs: 20 Participants: 4998 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
1 finding from 1 review
no estimate extracted
20 participants
Very low
Intervention not reported
Milnacipran standard dose RCTs: 8 Participants: 2491 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
1 finding from 1 review
no estimate extracted
8 participants
Very low
Intervention not reported
Duloxetine high dose RCTs: 10 Participants: 4000 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
1 finding from 1 review
no estimate extracted
10 participants
Very low
Intervention not reported
Duloxetine low dose RCTs: 6 Participants: 1031 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
1 finding from 1 review
no estimate extracted
6 participants
Very low
Intervention not reported
Milnacipran high dose RCTs: 7 Participants: 2837 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
1 finding from 1 review
no estimate extracted
7 participants
Very low
Intervention not reported
Amitriptyline standard dose RCTs: 10 Participants: 997 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
1 finding from 1 review
no estimate extracted
10 participants
Very low
Intervention not reported
Esreboxetine standard dose RCTs: 1 Participants: 783 · people with chronic pain Interventions: amitriptyline standard dose (25‐75 mg); desvenlafaxine high dose (> 50 mg); duloxetine low dose (<…
1 finding from 1 review
no estimate extracted
1 participants
Very low
Proportion of participants with IOP control (higher number of events is better) · Participants with acute primary angle closure after initial medical treatment to lower intraocular pressure
Phacoemulsification may leads to higher proportion of participants with IOP control (higher number of events… compared with laser peripheral iridotomy (low certainty).
1 finding from 1 review
Mean change in angle findings, measured by any method · Participants with acute primary angle closure after initial medical treatment to lower intraocular pressure
1 finding from 1 review
Adverse effects · Participants with acute primary angle closure after initial medical treatment to lower intraocular pressure
1 finding from 1 review
Clinical vertebral fractures · postmenopausal women at lower risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Non‐vertebral fractures · postmenopausal women at lower risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes non‐vertebral fractures compared with placebo (very low certainty).
1 finding from 1 review
RR 0.54 [0.22, 1.35]
Studies not reported
Very low
Hip Fracture · postmenopausal women at lower risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Wrist fractures · postmenopausal women at lower risk of fractures1
Risedronate 5 mg/day showed no clear difference in wrist fractures compared with placebo (low certainty).
1 finding from 1 review
RR 0.48 [0.03, 7.5]
Studies not reported
Low
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 0.67 [0.38, 1.18]
Studies not reported
Low